Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

From patient data to novel targets and biomarkers: UK Biobank use case. 

ET
60 Minutes

Traditional drug discovery is slow, costly, and often disconnected from the real biology of patients. However, biobank resources like the UK Biobank can help overcome current challenges by delivering access to vast genomic, proteomic, and phenotypic datasets. But the question is: How do we translate millions of patient data points into actionable discoveries?  

Join us for this valuable webinar for a deep dive into AI-powered biobank analysis. Learn how it enables the identification of causal pathways, discovery of novel subgroups, and smarter therapeutic decisions. We’ll explore strategies that will allow you to: 

  • Apply AI to large-scale patient data for uncovering hidden phenotypes and subgroups  

  • Leverage biobank insights to drive drug repurposing and indication expansion  

  • Accelerate target identification with proteomics-driven discovery 

  • And more 

Don’t miss out on real-world examples that show how AI-based analysis impacts novel discoveries based on patient data. Register today! 

Speakers

dawid-hs.png

Dawid Rymarczyk, PhD

Director of AI Solutions
Ardigen

Dawid has been part of Ardigen since 2017, combining deep AI expertise with strategic leadership. He holds a PhD in Artificial Intelligence and Computer Vision from Jagiellonian University and specializes in high-content imaging, digital pathology, and biomedical data. Dawid has led key projects, including multimodal fusion initiatives that integrate chemical structures, clinical data, and raw images. His work continues to shape innovative applications of AI in biotech and push the boundaries of data-driven drug discovery.

ardigan-hs-bart.png

Bart Smets, PhD

Director Neuroscience Data Science & Digital Health
Johnson & Johnson

He leads the Molecular Measures team that is focused on leveraging multi-omics signatures from large patient cohorts and preclinical models to identify new drug targets and to create novel patient stratification tools to enable precision neuroscience. Bart was trained as a bioengineer and bioformatician. He obtained a PhD in Sciences at the Catholic University of Leuven, Belgium. Bart has 15+ years of experience in biotech and pharma.

Register here!

Already registered? Click here to login.
Date/Time:
ET